(RTTNews) - Viatris (VTRS) said Wednesday that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in the class ...

* Mylan says authorized generic, which will reach pharmacies starting next week, has same drug formulation and device functionality as Epipen auto-injector Sign up here. * Authorized generic for ...

NEW YORK (CBSNewYork) — Meridian Medical Technologies, makers of Mylan's EpiPen Auto-Injector, have issued a voluntary recall of its EpiPen and EpiPen Jr. injectors. "The potential defect could make ...

June 29 (Reuters) - Drugmaker Sanofi SASY.PA asked a U.S. judge on Wednesday to curb Mylan's bid to recover litigation costs in an antitrust lawsuit, calling the rival pharmaceutical company's court ...

The U.S. Food and Drug Administration is alerting consumers to Meridian Medical Technologies' voluntary recall of 13 lots of Mylan's EpiPen and EpiPen Jr (epinephrine injection) Auto-Injector products ...

CVS Health, which owns more than 9,600 retail pharmacies and 1,100 walk-in clinics, will offer a lower-cost generic version of the Adrenaclick epinephrine auto-injector, targeting Mylan after the ...

Mylan NV's EpiPen product. PITTSBURGH — Mylan NV has reached a $465 million settlement with the U.S. Department of Justice over concerns about the classification of its EpiPen products used to treat ...

Pro Football Player Adrian Peterson is Calling on Americans to be Ready2Go™ and Learn How to be Aware and Prepared for Anaphylaxis PITTSBURGH, June 2, 2014 /PRNewswire/ -- Mylan Specialty, the fully ...

The FDA cleared the first generic version of EpiPen and EpiPen Jr, an epinephrine auto-injector for severe allergic reactions, 2 years after generic drugmaker Teva Pharmaceuticals was first turned ...

WASHINGTON, April 17 (Reuters) - The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA SASY.PA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc VTRS.O ...

Move over Martin Shkreli, there’s a new pharmaceutical villain in town. In an echo of the Turing Pharmaceuticals CEO’s headline-generating 2015 decision to boost the per-pill price of the drug ...